10-K: Adicet Bio Advances Autoimmune Therapies, Secures Funding

Adicet Bio reports positive preliminary Phase 1 results for prula-cel in autoimmune diseases, plans pivotal trials, and secures financing while facing substantial losses.

Summary

• Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
• The lead product candidate, prula-cel (CD20-targeting CAR gamma delta T cell therapy), is being developed for autoimmune diseases.
• The U.S. FDA cleared the Investigational New Drug (IND) application for prula-cel in lupus nephritis (LN) in December 2023.
• The prula-cel autoimmune clinical development program expanded in August 2024 to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV).
• Phase 1 clinical trial sites for prula-cel in autoimmune diseases were activated, and enrollment for LN patients opened in September 2024.
• An IND amendment was cleared in October 2024 to evaluate prula-cel in idiopathic inflammatory myopathies (IIM) and stiff person syndrome (SPS).
• The FDA granted Fast Track Designation to prula-cel for relapsed/refractory class III or class IV LN in June 2024, and for refractory SLE with extrarenal involvement and SSc in February 2025.
• Enrollment expanded to include SLE patients in April 2025, and the first SSc patient was dosed in July 2025.
• Positive preliminary results from seven SLE and LN patients in the ongoing Phase 1 trial were announced in October 2025 (data cut-off August 31, 2025).
• Alignment was reached with the FDA in November 2025 to allow LN and SLE patients to be dosed with prula-cel in the outpatient setting.
• The first patient was dosed in a Phase 1 clinical trial of prula-cel in treatment-refractory rheumatoid arthritis (RA) in October 2025.
• The company is advancing ADI-212, a gene-edited and armored clinical candidate targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer (mCRPC).
• Development of ADI-270 for metastatic/advanced clear renal cell carcinoma was discontinued in July 2025 due to strategic reprioritization, despite its Phase 1 trial showing a 100% disease control rate and 20% best overall response rate in five ccRCC patients with a favorable tolerability profile.
• Net loss for the year ended December 31, 2025, was $116.8 million, compared to $117.1 million for the year ended December 31, 2024.
• The accumulated deficit as of December 31, 2025, was $614.7 million.
• Cash, cash equivalents, and short-term investments totaled $158.5 million as of December 31, 2025.
• The company raised approximately $19.3 million net proceeds from an at-the-market (ATM) program in January 2024, $91.7 million net proceeds from an underwritten public offering in January 2024, and $74.8 million net proceeds from an underwritten registered direct offering in October 2025.
• A 1-for-16 reverse stock split was effected on December 30, 2025.
• The material weakness in internal control over financial reporting related to cash disbursements, identified in Q4 2024, was remediated as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While the company continues to incur significant losses, the promising early clinical data for prula-cel in autoimmune diseases, multiple Fast Track designations, and successful capital raises provide a solid foundation for future development. The strategic pipeline prioritization and FDA alignment for outpatient dosing are also favorable. However, the early stage of development, high cash burn, and inherent risks of novel therapies temper the overall sentiment.

Positives

• Positive preliminary Phase 1 results for prula-cel in seven SLE and LN patients were announced in October 2025, indicating potential efficacy in autoimmune diseases.
• Prula-cel received Fast Track Designation from the FDA for relapsed/refractory class III or class IV LN in June 2024, and for refractory SLE with extrarenal involvement and SSc in February 2025, which may expedite development and review.
• The FDA aligned with the company in November 2025 to allow outpatient dosing for LN and SLE patients with prula-cel, suggesting a favorable tolerability profile and potential competitive advantage.
• The discontinued ADI-270 Phase 1 trial demonstrated a 100% disease control rate and 20% best overall response rate in five ccRCC patients, with a favorable tolerability profile (no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome).
• The company's cash, cash equivalents, and short-term investments of $158.5 million as of December 31, 2025, are expected to fund operations into the second half of 2027.
• Successful capital raises in January 2024 (approx. $19.3M ATM, $91.7M public offering) and October 2025 (approx. $74.8M registered direct offering) strengthened the financial position.
• The material weakness in internal control over financial reporting related to cash disbursements was remediated as of December 31, 2025, indicating improved financial controls.

Negatives

• The company incurred significant net operating losses of $116.8 million in 2025 and $117.1 million in 2024, with an accumulated deficit of $614.7 million as of December 31, 2025.
• Development of ADI-270 was discontinued in July 2025 due to strategic reprioritization, leading to the closure of its Phase 1 clinical trial.
• Interest income decreased by $4.9 million (46%) in 2025, primarily due to lower interest rates and lower cash balances.
• A workforce reduction plan was implemented in July 2025, incurring approximately $2.3 million in one-time severance benefits.
• A stock option repricing in August 2023 resulted in $4.6 million of incremental compensation cost.
• Certain executive officers surrendered underwater stock options in August 2024 and November 2025, reflecting previous declines in the company's stock price.

Risks

• The company has a limited operating history and faces significant challenges and expenses in building its capabilities.
• Business is highly dependent on the success of prula-cel; failure to obtain regulatory approval or commercialize would significantly harm the business.
• Gamma delta T cell candidates represent a novel approach, creating significant challenges for treating autoimmune diseases and cancer.
• Product candidates are based on novel technologies, making it difficult to predict likely success, time, and cost of development and regulatory approval.
• Clinical trials may fail to demonstrate the safety and efficacy of any product candidates, preventing or delaying regulatory approval and commercialization.
• May not be able to file IND applications or comparable regulatory submissions on expected timelines, or regulatory authorities may not permit proceeding.
• May encounter substantial delays in clinical trials or may not be able to conduct trials on expected timelines.
• Market opportunities for product candidates may be limited to patients ineligible for or who have failed prior treatments and may be small.
• May not realize the anticipated benefits of workforce reduction and strategic pipeline prioritization.
• Dependence on third-party suppliers and manufacturers increases the risk of insufficient quantities or unacceptable costs for product candidates.
• Highly dependent on key personnel; failure to attract and retain qualified personnel may impede business strategy.
• Will need substantial additional financing; failure to obtain it may prevent completion of development and commercialization.
• The pharmaceutical industry in China is highly regulated, and changes in regulations (e.g., Foreign Investment Law, negative list) may affect development, approval, and commercialization.
• Uncertainties in China's legal system regarding the Foreign Investment Law may subject contractual arrangements to different interpretations or enforcement challenges, or severe penalties.
• Business disruptions, including armed conflicts, could substantially delay clinical trials or seriously harm future revenue and financial condition.
• Risks associated with conducting research and clinical trials abroad and marketing internationally, including the potential impact of global conflicts on supply or clinical trials.
• Past failure and potential future failure to achieve and maintain effective internal control over financial reporting could harm business and negatively impact stock value.
• Termination or material breach of the collaboration with Regeneron Pharmaceuticals, Inc. would materially harm business.
• Existing and future collaborations are important; inability to maintain or success of collaborations could adversely affect business.
• The FDA regulatory approval process is lengthy and time-consuming, with potential for significant delays.
• Efforts to protect intellectual property may be inadequate, hindering effective competition.
• Dependence on intellectual property licensed from third parties; termination of licenses could result in the loss of significant rights.
• Trading price of common stock is highly volatile, potentially leading to substantial losses and securities class action litigation.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and stock price.
• Inadequate funding and/or staffing for the FDA, SEC, and other government agencies could hinder timely product development/commercialization.
• Relationships with customers, physicians, CROs, and third-party payors are subject to federal and state healthcare fraud and abuse laws; violations could lead to substantial penalties.
• Data protection, privacy, and similar laws restrict access, use, and disclosure of information; failure to comply could materially harm business.
• Artificial intelligence presents risks and challenges that can impact business, including security risks to confidential information and an uncertain regulatory environment.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited by ownership changes.
• Changes in U.S. patent law could diminish the value of patents in general.
• May not be able to protect intellectual property rights throughout the world.
• May be subject to claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Sales of a substantial number of shares of common stock by existing stockholders in the public market could cause the stock price to fall.
• Broad discretion over the use of cash, cash equivalents, and short-term investments, which may not be used effectively.
• No anticipated cash dividends on capital stock in the foreseeable future.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, share price and trading volume could decline.
• Product liability lawsuits could incur substantial liabilities and may require limiting commercialization.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• The Delaware Forum Provision could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Status as a Smaller Reporting Company (SRC) and reduced disclosure requirements may make common stock less attractive to investors.

Future Outlook

The company expects to incur significant expenditures and net losses for the foreseeable future, with these expenditures increasing as development and regulatory approvals for product candidates continue. It aims to submit a new regulatory submission, such as an IND application or equivalent, every 12-18 months. Specific plans include meeting with the FDA in Q2 2026 to inform potential pivotal trial design for prula-cel, with an expected initiation of a pivotal study in LN or LN and SLE patients in H2 2026, subject to regulatory clearance. Clinical updates for prula-cel in LN, SLE, and SSc patients are expected in H1 2026, with an additional update in H2 2026, and for RA in H2 2026. A regulatory filing for ADI-212 for mCRPC is expected in Q3 2026, with patient enrollment anticipated in Q4 2026. The company plans to continue innovating and investing in its gamma delta T cell platform and pipeline, including gene-edited CAR T and in vivo CAR T programs, and expects to expand human capital resources in 2026.

Management Comments

• We believe the favorable safety profile, cellular kinetics and B cell depletion in peripheral blood and secondary lymphoid tissue demonstrated with prula-cel clinical experience to date is favorable for development in autoimmune diseases.
• We believe the potential market opportunity for prula-cel in B cell mediated autoimmune diseases is substantial based on the prevalence in the U.S., EU5, China and Japan of greater than 1.7 million patients.
• We believe the potential market opportunity for ADI-212 in mCRPC is significant based on the prevalence in the U.S., EU5, China and Japan of approximately 75,000 patients with second or third line advanced disease.
• We believe this would represent a significant competitive advantage for our gamma delta T cell-based therapies as compared to existing approved CAR T-cell therapy or other therapies.
• We believe that the manufacturing processes we are developing will be able to be completed in approximately two to three weeks and will result in sufficient quantities of drug product to treat numerous patients.
• We consider our relationship with our employees to be good.
• We are committed to pay equity, regardless of gender, race/ethnicity, or sexual orientation and conduct comprehensive pay equity analyses on a semi-annual basis.
• We believe that investing in our employees career growth provides individuals and the organization with the knowledge and skills to respond effectively to current and future business demands and support the organizations development efforts.
• We believe that our cash, cash equivalents and short-term investments will be sufficient for us to fund our operations for at least twelve months from the issuance date of our consolidated financial statements for the year ended December 31, 2025.

Industry Context

StockSavvy.ai notes that Adicet Bio is positioning its allogeneic gamma delta T cell therapies as a novel approach to overcome limitations of autologous CAR T-cell therapies, such as individualized manufacturing delays, variability, high costs, and scalability issues. The company's focus on autoimmune diseases with prula-cel aligns with a growing industry interest in CAR T for these indications, following durable proof-of-concept data from academic studies. The discontinuation of ADI-270 reflects a broader industry trend of strategic pipeline prioritization to optimize resource allocation in a capital-intensive sector. The FDA's alignment for outpatient dosing for LN and SLE patients with prula-cel could be a significant competitive advantage, addressing a key barrier to broader adoption of cell therapies.

Comparison to Industry Standards

• Prula-cel's exposure, measured by Cmax, D28 persistence, and area under curve, has been consistent with values reported for approved autologous CD19 CAR T therapies.
• Prula-cel's clinical B-cell depletion data in lymphoma mirrors the B-cell depletion reported in academic studies of autologous CD19 CAR-T in lupus patients.
• In lymphoma patients, prula-cel has demonstrated deep cytoreductive complete responses that surpassed the depth of response demonstrated by autologous CAR T therapy in the same patient.
• Gamma delta T cells offer potential advantages over NK cell-based therapies, including correlation with positive clinical outcomes in tumors and disease-associated tissues, secretion of multiple potent cytotoxic cytokines (e.g., interferon-gamma), production as highly homogeneous cell populations, predominant expression of activating receptors, and adaptive immunity features (TCR-mediated, MHC-independent antigen recognition, long lifespan, persistence).
• Gamma delta T cells offer potential advantages over alpha beta T cells (used in many allogeneic CAR T approaches) by not relying on genetic manipulations to inactivate the alpha beta TCR, displaying properties of both adaptive and innate immune systems, potentially being less prone to exhaustion and persisting longer, maintaining the capacity to home to tissues and tumors, and being less likely to induce cytokine release syndrome due to more limited endogenous IL-6 secretion.
• Gamma delta T cells offer potential advantages over bispecific antibody T cell recruitment for tumor immunotherapy by not relying on functional T cells derived from the patient, displaying properties of both adaptive and innate immune systems, maintaining the capacity to home to tissues and tumors, and being less likely to induce cytokine release syndrome.
• Adicet's gamma delta T cell technology differentiates from competitors through its robust and practical proprietary antibody-based manufacturing method, large-scale expansion of blood-derived gamma delta T cells, ability to selectively expand multiple gamma delta T cell subpopulations including highly potent V1 cells, absence of potentially pro-tumorigenic or pro-autoimmune Th17-type responses in its V1 subpopulation, in-house CAR target identification and verification process, and ability to effectively target tumor-specific intracellular protein-derived peptides using proprietary T cell receptor-like (TCRL) antibodies.

Corporate Governance

Related Party Transactions

• Regeneron Pharmaceuticals, Inc. owned 60,511 shares of the company's common stock as of December 31, 2025.
• Regeneron became a related party in July 2019 as a result of Series B redeemable convertible preferred stock financing.
• No revenue was recorded from the Regeneron Agreement for the year ended December 31, 2025.

Stakeholder Impact

• Shareholders: Experienced dilution from recent equity offerings and a 1-for-16 reverse stock split. The stock price remains highly volatile, influenced by clinical trial results and market conditions. Anti-takeover provisions may limit their ability to influence corporate control.
• Employees: A workforce reduction plan was implemented in July 2025, impacting some employees. The company offers competitive compensation, including equity grants, and invests in professional development, but competition for skilled personnel is intense.
• Patients: Potential for novel allogeneic gamma delta T cell therapies (prula-cel, ADI-212) for serious autoimmune diseases and cancer, with promising early safety and efficacy data. Outpatient dosing for prula-cel could improve patient access and convenience.
• Collaborators (e.g., Regeneron, CRISPR, City of Hope, Twist Bioscience): Continued strategic agreements provide access to technology, expertise, and potential funding, but also involve shared risks and payment obligations.
• Creditors: The company has repaid outstanding indebtedness to Banc of California, reducing debt obligations, but continues to require substantial additional financing for future operations.

Next Steps

• Meet with the FDA in Q2 2026 to inform potential pivotal trial design for prula-cel.
• Initiate a potential pivotal study in LN or LN and SLE patients in H2 2026, subject to regulatory clearance.
• Provide a clinical update for prula-cel in LN, SLE, and SSc patients in H1 2026.
• Provide an additional clinical update for prula-cel in LN, SLE, and SSc patients in H2 2026.
• Expect the next clinical update on prula-cel in RA in H2 2026.
• Submit a regulatory filing for ADI-212 for mCRPC in Q3 2026.
• Initiate patient enrollment for ADI-212 in Q4 2026, subject to regulatory clearance.
• Aim to submit a new regulatory submission (e.g., IND) every 12-18 months.
• Continue to innovate and invest in the gamma delta T cell platform and pipeline.
• Continue to develop product candidates in autoimmune diseases and cancer based on T cell platforms.
• Expand and protect intellectual property.
• Expand manufacturing capability through agreements with CDMOs and internal infrastructure.
• Continue to add to human capital resources in 2026.

Key Dates

Recommendation

Adicet Bio presents a mixed financial and operational picture. While the company has secured significant financing and reported promising early-stage clinical data for prula-cel in autoimmune diseases, it continues to incur substantial losses and operates in a high-risk, capital-intensive industry. The strategic pipeline prioritization and FDA's positive stance on outpatient dosing are favorable, but the long and uncertain path to regulatory approval and commercialization for novel therapies warrants a cautious approach. Investors should hold, awaiting further de-risking clinical data and clearer paths to profitability.

Keywords

gamma delta T cell therapy, autoimmune diseases, cancer, prula-cel, ADI-001, CD20, lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathies, stiff person syndrome, anti-neutrophil cytoplasmic autoantibody associated vasculitis, rheumatoid arthritis, ADI-212, PSMA, metastatic castration-resistant prostate cancer, allogeneic CAR T cell, biotechnology, clinical stage, Fast Track Designation, CRISPR, Regeneron, stock split, financing, SEC filing, 10-K